Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22 2021 - 8:00AM
Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage
company developing precision oncology therapeutics, today announced
that Avanish Vellanki, co-founder, chairman and chief executive
officer of Rain, will present at the Cantor Fitzgerald Virtual
Global Healthcare Conference being held virtually September 27-30,
2021.
Additional details can be found below:
Date: Thursday, September 30,
2021Time: 10:00 a.m. ETLocation:
Webcast Link – or at the company’s website (click here)
A replay of the presentation will be available by visiting the
"Events & Presentations" section of the Rain website after the
conclusion of the presentation and will be archived on the Rain
website for 30 days.
About Rain Therapeutics Inc.Rain Therapeutics
Inc. is a late-stage precision oncology company developing
therapies that target oncogenic drivers for which it is able to
genetically select patients it believes will most likely benefit.
This approach includes using a tumor-agnostic strategy to select
patients based on their tumors’ underlying genetics rather than
histology. Rain’s lead product candidate, milademetan, is a small
molecule, oral inhibitor of MDM2, which is oncogenic in numerous
cancers. In addition to milademetan, Rain is also developing a
preclinical program that is focused on inducing synthetic lethality
in cancer cells by inhibiting RAD52.
Media ContactJordyn TemperatoLifeSci
Communications+1.646.876.5196jtemperato@lifescicomms.com
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rain Oncology (NASDAQ:RAIN)
Historical Stock Chart
From Apr 2023 to Apr 2024